Targeting the inactive conformation of protein kinases: computational screening based on ligand conformation
暂无分享,去创建一个
[1] Malcolm J. McGregor,et al. A Pharmacophore Map of Small Molecule Protein Kinase Inhibitors , 2007, J. Chem. Inf. Model..
[2] Ji-Xia Ren,et al. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. , 2009, Journal of molecular graphics & modelling.
[3] G. Müller,et al. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition , 2008, Expert opinion on drug discovery.
[4] Konstantin V Balakin,et al. VEGF/VEGFR signalling as a target for inhibiting angiogenesis , 2007, Expert opinion on investigational drugs.
[5] Daniel Rauh,et al. A new screening assay for allosteric inhibitors of cSrc. , 2009, Nature chemical biology.
[6] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[7] Richard Kendall,et al. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. , 2007, Journal of medicinal chemistry.
[8] P. Bohlen,et al. Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2. , 2009, Bioorganic & medicinal chemistry.
[9] J. A. Grant,et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.
[10] Pascal Bonnet,et al. Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors , 2011, J. Comput. Aided Mol. Des..
[11] Taebo Sim,et al. A general strategy for creating "inactive-conformation" abl inhibitors. , 2006, Chemistry & biology.
[12] A. Kiselyov,et al. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. , 2005, Bioorganic & medicinal chemistry letters.
[13] Ping Chen,et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase in , 2006, Journal of medicinal chemistry.
[14] Scott P. Brown,et al. A unified, probabilistic framework for structure- and ligand-based virtual screening. , 2011, Journal of medicinal chemistry.
[15] N. Gray,et al. Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.